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1 INTRODUCTION 
Development of a formulation involves a great deal of study and experimental 
work to get optimum results. While doing so we have to keep in mind various factors 
are considered like choice of excipients, drug bioavailability, drug stability in required 
dosage form, cost effectiveness, manufacturing aspects. 
 Now a day’s formulation research is breaking barriers of conventional 
methods. Present day’s drugs can be delivered with a convenience manner, 
performance and bioavailability
1
. 
Drugs have been applied to the mucosa for topical application for many years. 
However, recently there has been interest in exploiting the oral cavity as a portal for 
delivering drugs to the systemiccirculation
2
. 
 
The Drug delivery through sublingual route have desire to provide quick onset 
of pharmacological effect. Dysphasia (difficulty in swallowing) is a common problem 
of all age groups, especially elderly, children, and patients who are mentally retarted, 
un cooperative, nauseated or on reduced liquid‐ intake/diets have difficulties in 
swallowing these dosage forms. Sublingual administration of the drug means 
placement of the drug under the tongue and drug reaches directly in to the blood 
stream through the ventral surface of the tongue and bottom of the mouth
3
.  
The sublingual route usually produces a faster onset of action than the orally 
ingested tablets and the portion absorbed through the sublingual blood vessels 
bypasses the hepatic first‐pass metabolic processes4. 
 
1.1.Oral Mucosa  
 
The oral cavity comprises the lips, cheek, tongue, hard palate, soft palate and 
floor of the mouth. The lining of the oral cavity is referred to as the oral mucosa, and 
includes the buckle, sublingual, gingival, palatal and labial mucosa. The oral mucosa 
top quarter to one-third is made up of closely compacted epithelial cells. The main 
role of the oral epithelium is to protect fluid loss and underlying tissue against 
potential harmful agents in the oral environment. Beneath the epithelium is the 
basement membrane, lamina propia and submucosa. The oral mucosa also having 
many taste receptors of the tongue and sensory receptors. 
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The lining mucosa is found in the outer oral vestibule (the buckle mucosa) and 
the sublingual region (floor of the mouth) The specialized mucosa is found on the 
dorsal surface of tongue, while the masticatory mucosa is found on the hard palate 
(the upper surface of the mouth) and the gingiva (gums). The lining mucosa 
comprises approximately 60%, the masticatory mucosa approximately 25%, and the 
specialized mucosa approximately 15% of the total surface area of the oral mucosal 
lining in an adult human. The masticatory mucosa is located in the regions 
particularly susceptible to the stress and strains resulting from masticatory activity. 
The superficial cells of the masticatory mucosa are keratinized, and a thick lamina 
propia tightly binds the mucosa to underlying periosteum. The mucosa of the dorsum 
of the tongue is specialized gustatory mucosa’s, which has a well papillae surface; 
which are both keratinized and some non-keratinized
5
. 
 
Whereas keratinized regions contain predominantly neutral lipids 
(creaminess). Non-keratinized areas are composed of glycosylceramides that appears 
to be derived from membrane coating granules that differ morphologically from the 
lamellate membrane coating granules of keratinized tissue.  
 
The amount of a certain drug absorbed through the oral mucosa is determined 
by many factors, including the pKa of the base, the rate of partition of the unionized 
form of the drug, the lipid – water partition coefficient of that particular drug, and 
lastly, on the pH of the solution
6
.  
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Figure No. 1: Schematic representation of the different linings of mucosa in 
mouth 
  
1.2.The oral mucosal cavity, delivery of drugs is classified into three categories: 
 Sublingual delivery: which is systemic delivery of drugs through the mucosal 
membranes lining the floor of the mouth. 
 Buccal delivery: which is drug administration through the mucosal 
membranes lining the cheeks (buckle mucosa), and  
 Local delivery: which is drug delivery into the oral cavity7 
 
1.3.Advantages: 
 Rapid onset of effect - particularly for pain, emesis, insomnia or allergy relief. 
 Easy, painless and convenient self-administration. 
 To get pharmacological effect with less drugs, less side effect. 
 Inexpensive to manufacture per dose. 
 Flexible formulation options. 
 The blood supply is rich with a capillary network close to mucosa6 
 To easy administration such as geriatric, pediatric and psychiatric patients.  
 A relatively rapid onset of action can be achieved compared to the oral route, 
and the formulation can be removed if therapy is required to be discontinued.  
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 Due to more contact surface area of oral cavity it provide good absorption. 
 Liver is bypassed and also drug is protected from degradation due to pH and 
digestive enzymes of the middle gastrointestinal tract.  
 They also present the advantage of providing fast dissolution or disintegration 
in the oral cavity, without the need for water or chewing
8
.  
 
1.4.Disadvantages: 
 
 It is difficult to convert a high dose poorly compressible API into a tablet of 
suitable size for human use. 
  Difficult to formulate a drug with poor wettability, slow dissolution into a 
tablet. 
 To show Slow onset of action as compared to parenterals, liquid oral form and 
capsules. 
  Patients cannot undergoing radiotherapy swallow tablet. 
 
1.5.Sublingual Absorption  
 Sublingual, meaning literally 'under the tongue' refers to a method of 
administering substances via the mouth in such a way that the substances are rapidly 
absorbed via the blood vessels under the tongue rather than via the digestive tract 
However, not all substances are permeable and accessible to oral mucosa
3
. 
Sublingual drug administration is applied in the field of cardiovascular drugs, 
steroids, some barbiturates and enzymes. It has been a developing field in the 
administration of many vitamins and minerals which are found to be readily and 
thoroughly absorbed by this method. Sublingually absorbed nutrition, which avoids 
exposure to the gastric systemand liver, means direct nutritional benefits, particularly 
important for sufferers of gastro‐intestinal difficulties such as ulcers, hyperactive gut, 
coeliac disease, and digestion, the elderly and invalids the nutritional advantage is 
independent of gastro‐intestinal influences. Examples of drugs administered by this 
route include antianginal like nitrites and nitrates, anti hypertensive like nifedipine, 
analgesics like morphine and bronchodilators like fenoterol. Certain steroids like 
estradiol and peptides like oxytocin can also be administered e.g. fentanyl citrate, 
apomorphine, prochlorperazinedimaleate (PRO), and hydrazine HCl
8,6 
. 
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Glyceryltrinitrate one of the best used regularly it is rapid symptomatic relief of 
angina and potent coronary vasodilator. It has been found impressively effective when 
administered sublingually; pharmacologically active after only 1 – 2 minutes. The 
rapid relief of symptoms an aerosol spray was found due to first pass metabolism. The 
extent of first pass metabolism when compare to sublingual spray decreased to 48% 
with sublingual tablets and 28% with oral dose. Following sublingual administration, 
nitrates après in plasma concentrations can be maintained 24 hours. Sublingual 
varapamil was effective in controlling the ventricular rate following sublingual 
administration
3
.   
 
 
Figure No. 2: Diagram of Sublingual Gland and Sublingual Artery 
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1.6.The mechanism of sublingual absorption 
 
The cells of the oral epithelium and epidermis are also capable of absorbing by 
endocytosis (the uptake of particles by cells. These engulfed particles are usually too 
large to diffuse through its wall). However, it is believed that acidic stimulation of the 
salivary glands, with the additional vasodilatation, facilitates absorption and uptake 
into the circulatory system. The salivary glands consist of lobules of cells which 
produce saliva through the salivary ducts into the mouth. The three pairs of salivary 
glands are present i.e. the parotid, the submandibular and the sublingual which lies on 
the floor of the mouth. The more acidic the taste, the greater the stimulation of 
salivary output; serving to avoid potential harm to acid‐sensitive tooth enamel by 
bathing the mouth in copious neutralizing fluid The mouth is lined with a mucous 
membrane which is covered with squamous epithelium and contains mucous glands. 
The sublingual mucosal tissue is similar to that of buckle mucosa. In order for a drug 
to be effectively absorbed sublingually, it needs to be able to travel across the buckle 
mucous membranes; by a process of diffusion known as osmosis governing both 
intestinal and sublingual absorption.  
 
1.6.1. Osmosis: 
The present of water across cell walls mainly depends on the osmotic 
difference in the blood between the extracellular and intracellular fluid. Small 
particles that readily dissolve in water, rarely present a difficulty in permeation and 
diffusion, and so are able to move easily between the tissues of the body. Active 
transportation into cells leads to rapid metabolism of the substances. Molecules such 
as glucose (fructose) and amino acids are essential for cell metabolism and special 
mechanisms have evolved to facilitate their rapid diffusion and permeation across 
cellmembranes7.The main mechanism for the absorption of the drug in to oral mucosa 
is via passive diffusion into the lipoidal membrane .The absorption of the drug 
through the sublingual route is 3 to10 times greater than oral route and is only 
surpassed by hypodermic injection
9, 10
. 
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1.7.Superdisintegrants 
There has been a considerable demand for faster disintegrating formulations 
and faster dissolution, hence the need to formulate modified disintegrates with still 
higher efficacies has lead to the new generation of Superdisintegrants at low 
concentration have greater disintegrating efficiency. They are more effective intra 
granularly and exert less effect on compressibility and flow ability. But 
superdisintegrants have some drawbacks - they are hygroscopic therefore not used with 
moisture sensitive drugs, functionality is not as desired at higher concentrations and 
some are anionic and may cause some cationic drugs slight in-vitro binding.  
        These superdisintegrants act by swelling and due to swelling pressure exerted in 
the outer direction or radial direction, it causes tablet to burst or the accelerated 
absorption of water leading to an enormous increase in the volume of granules to 
promote disintegration
10
. 
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Table No. 1: List of super disintegrants 
Superdisintegrants Example 
Mechanism Of 
Action 
Special comment 
Crosscarmellose 
Ac-Di-Sol 
Nymce ZSX 
PrimelloseSolutab 
VivasolL-HPC 
Crosslinked 
Cellulose 
Swells 4-8 folds 
in< 10 seconds. 
Swelling and 
wicking both. 
Swells in two 
dimensions. 
Direct compression or 
granulation 
Starch free 
Crosspovidone 
Crosspovidon M 
Kollidon 
Polyplasdone 
Crosslinked 
PVP 
Swells very little 
and returns to 
original size 
after compression 
but act by 
capillary action 
Water insoluble and 
spongy in nature so get 
porous tablet 
 
Sodium starch 
glycol ate 
Exploitable 
Primo gel 
Crosslinked 
Starch 
Swells 7-12 folds 
in < 30 seconds 
Swells in three 
dimensions and high 
level serve as sustain 
release matrix 
 
Algonac acid NF 
Satialgine 
Crosslinked 
alginic acid 
Rapid swelling in 
aqueous medium 
or wicking action 
Promote disintegration 
in both dry or wet 
granulation 
 
Soy polysaccharides 
Emcosoy 
Natural 
super 
Disintegrant 
 
Does not contain any 
starch or sugar. Used in 
nutritional products. 
Calcium silicate 
 
 
Wicking 
Action 
Highlyporous,Optimum 
concentration is between 
20-40% 
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1.8.Sublingual Dosage Forms: 
 Drugs administered by this route rapid produce systemic/ local effects. In 
general, absorption form this route is observed because of the thin mucous membrane 
and rich blood supply. 
The sublingual dosage forms can be classified into the following:  
• Sublingual Tablets 
• Sublingual Spray 
• Sublingual Capsules 
• Sublingual Films 
Sublingual Tablets: 
Sublingual tablets are intended to be placed beneath the tongue and held until 
Absorption has taken place. They must dissolve or disintegrate quickly, allowing the 
medicament to be rapidly absorbed.  
Sublingual Spray: 
 Sublingual sprays are the dosage forms in which the drug is dissolved or 
dispersed in a vehicle and filled in vial with metered value. On actuation a desired 
dose of the drug will deliver through the valve.  
Sublingual Capsules: 
  These are the solid dosage forms in which the powder was filled into capsule, 
it should be cut open and the contents are poured below the tongue. e. g. Nifedipine 
sublingual capsule. 
Sublingual Films: 
 These are the thin, transparent films, which are kept under the tongue form 
which drug will reach and absorbed into blood stream. e. g. diazepam 
11 
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1.9.Formulation of sublingual tablets 
The formulation of sublingual tablets involves the selection of suitable 
excipients of bland taste that shall ultimately resulting in a rapid disintegrating tablet 
their by enhancing the dissolution of active ingredient. There are two different types 
of sublingual Tablets
13,14
. 
A. Molded Sublingual Tablets 
B. Compressed Sublingual Tablet 
1. Molded Sublingual Tablets 
 The sublingual tablets are usually prepared from soluble ingredients so that the 
tablets are completely and rapidly soluble. They contain, in addition of drug, 
excipients or base namely lactose, dextrose, sucrose, Mannitol. This tablet shows the 
same bioavailability as conventional tablets but has the advantage of markedly 
improved stability. 
2. Compressed Sublingual Tablets  
 
 The compressed sublingual tablets are speed of absorption and a 
correspondingly rapid physiological response, which are normally best achieved with 
a rapidly soluble. Compressed sublingual tablets can be prepared by two different 
methods: 
a) Wet Granulation Method 
b) Direct Compression Method. 
Wet Granulation Method: 
 The excipients and drugs to get uniform mixture to passed through particular 
sieve. Suitable granulating agents like water, starch paste, providence can be added to 
the powder mixture in the appropriate proportion to produce a coherent mass. This 
mass is passed through a suitable sieve and dried at optimum temperature and sieved 
to get uniform granules. Then the granules are lubricated and compressed into a 
tablet. 
  
Department Of Pharmaceutics                                                                     Introduction 
 
Annai Veilankanni’s Pharmacy College ,Chennai  11 
 
Direct Compression Method: 
The term direct compression is used to define a process by which tablets are 
compressed directly from the powder blends of active ingredients and suitable 
excipients, which will flow uniformly into the die cavity and compact. The great 
advantage of direct compression is the manufacturing cost. It uses conventional 
equipment, commonly available excipients, and a limited number of process steps. 
Direct compression is the easiest way to manufacture tablets and also fast melting 
tablets. 
3. Freeze drying / lyophilization: 
Lyophilization is used to prepare tablets that have porous open matrix network 
into which saliva rapidly disperses when placed in mouth. The drug is incorporate in a 
matrix water soluble which is freeze dried to make a unit which rapidly disperses 
when take in mouth. Apart from the matrix and active constituents, the final 
formulation may contain other excipients, which improve the process characteristics 
or enhance the quality of the final product. These include suspending agents, wetting 
agents, preservatives, antioxidants, colours and flavours. The preferred drug 
characteristics for freeze drying formulations are water in solubility, low dose, 
chemically stable, small particle size. The freeze-drying technique has demonstrated 
improved absorption and increase in bioavailability
12 
4. Sublimation:  
 Sublimation technique is addition of a volatile salt to the tabletting component, 
mixing the components to obtain a substantially homogenous mixture and volatizing 
salt. The removal of volatizing salt creates pores in the tablet, which help in achieving 
rapid disintegration when the tablet comes in contact with saliva. The tablets were 
then subjected to vacuum at 80º C for 30 minutes to eliminate volatile components 
and thus create pores in the tablet. Volatile salts such as camphor, ammonium 
bicarbonate, naphthalene, urea, etc., were also used as sublimable components to 
prepare porous. 
5. Spray drying: 
Spray drying produces highly porous and fine powder as the processing 
solvent is evaporated during process. Spray dryers are widely used in pharmaceuticals 
and biochemical process. Spray drying can be used to prepare rapidly disintegrating 
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tablets by using support matrix such as hydrolyzed an non hydrolyzed gelatin and 
other components like Mannitol as bulking agent, sodium starch glycolate, 
Crosscarmellose sodium as disintegrants, acidic material like citric acid and alkali like 
sodium bicarbonate to enhance disintegration and dissolution
13
. 
6. Mass Extrusion 
This technology involves softening of the active blend using the solvent 
mixture of water soluble polyethylene glycol, using methanol and expulsion of 
softened mass through the extruder or syringe to get a cylinder of the product into 
segments using heated blade to form tablets. The dried cylinder can also be use to 
coating granules of bitter tasting drugs and there by masking bitter taste
12
. 
 
1.10. Mechanism of superdisintegrants 
There are four main mechanisms for tablets disintegration as follows 
1. Swelling: 
  The most accepted general mechanism of action for tablet disintegration is 
swelling. The tablets with high porosity nature show poor disintegration due to have 
lack of adequate swelling force. On the other hand, sufficient swelling force is exerted 
in the tablet with low porosity. Note that if the packing fraction is very high, fluid is 
unable to penetrate in the tablet and disintegration is again slows down
14
. 
2. Porosity and capillary action (Wicking): 
Disintegration by capillary action is always the first step. When we put the 
tablet into suitable aqueous medium, the medium penetrates into the tablet and 
replaces the air adsorbed on the particles, which weakens the intermolecular bond and 
breaks the tablet into fine particles. The water up take by tablet mainly depends upon 
hydrophilicity of the drug/excipients and tableting conditions. 
3. Disintegrating particle/particle due to repulsive forces: 
             The another mechanism of tablet disintegration attempts to explain the 
swelling of tablet made with ‘non-swellable’ disintegrants. Particle repulsion theory 
based on the observation that non swelling particle also cause disintegration of tablets. 
Water is required for The electric repulsive forces between particles are the 
mechanism of disintegration. Wicking is secondary. 
 
Department Of Pharmaceutics                                                                     Introduction 
 
Annai Veilankanni’s Pharmacy College ,Chennai  13 
 
4. Due to deformation: 
During tablet compression, disintegrated particles get deformed and these 
deformed particles get into their normal structure when they come in contact with 
aqueous media or water. The swelling capacity of starch was improved when granules 
were extensively deformed during compression. This increase in size of the deformed 
particles produces a break up of the tablet
10
. 
 
Literature Review
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2. LITERATURE REVIEW 
J.Nikunj et al. (2012) Now a day’s formulation research is breaking barriers of 
conventional methods. First pass metabolism can be overcome by sublingual drug 
delivery, and quick drug delivery into the systemic circulation can be obtained. 
Sublingual administration can offer an attractive alternative route of administration. 
The advantage of the sublingual drug delivery is that the drug can be directly 
absorbed into systemic circulation bypassing enzyme degradation in the gut and liver. 
These formulations are particularly beneficial to pediatric and geriatric patients. the 
sublingual region allow excellent drug penetration to achieve high plasma drug 
concentration In addition sublingual mucosa and abundance of blood supply and show 
rapid onset of an action
1
.  
K.patel Nibha et al. (2012) Oral mucosal drug delivery is an alternative and 
promising method of systemic drug delivery which offers several advantages. 
Sublingual literally meaning is ''under the tongue'', administrating substance via 
mouth in such a way that the substance is rapidly absorbed via blood vessels under 
tongue. Sublingual route offers advantages such as bypasses hepatic first pass 
metabolic route which gives better bioavailability, quick onset of action, patient 
fulfillment, self-medicated. Dysphasia (difficulty in swallowing) is common between 
in all ages of people and more in pediatric, geriatric, psychiatric patients. Sublingual 
area of oral cavity is more permeable compare to buccal and palatal area
2
. 
Nehanarang et al. (2010) Drug delivery system are becoming more complex as 
pharmaceutical scientist acquire better understanding of the physiochemical and 
biochemical parameters pertinent to their performance. Over the last decade, the 
demand of fast disintegrating tablet has been growing mainly for geriatric and 
pediatric patients, because of swallowing difficulties, the characteristics of fast 
disintegrating tablet for potential emergency treatment. The superdisintegrants used in 
this study was Crosspovidone. The tablets were evaluated for weight variation, 
hardness, friability, wetting time, water absorption ratio, and disintegration time and 
dissolution study. The tablets were prepared by wet granulation procedure. The 
systematic formulation approach helped in understanding the effect of formulation 
processing variables
3
. 
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Amitkumar et al. (2013) Sublingual tablets offer fast release of drug from the 
formulation and it reaches systemic circulation directly, which bypasses the 
metabolism of drug in liver. The demand of fast disintegrating sublingual tablets has 
been growing, during the last decade especially for geriatric and pediatric patients 
because of swallowing difficulties. Drug delivery system are becoming more complex 
as pharmaceutical scientist acquire better understanding of the physiochemical and 
biochemical parameters pertinent to their performance. Various techniques can be 
used to formulate sublingual tablets i.e. direct compression, freeze drying etc. The 
sublingual tablets require faster disintegration. So, we need to formulate disintegrates 
i.e. superdisintegrants which are effective at low concentration and have greater 
disintegrating efficiency
4
.  
F.Viralkumar et al. (2010) Oral transmucosal delivery, especially buccal and 
sublingual delivery, has progressed far beyond the use of traditional dosage forms 
with novel approaches emerging continuously. the advances and opportunities for 
buccal/sublingual drug delivery. The advances and opportunities for buccal/sublingual 
drug delivery This review highlights the challenges as well as Particular attention is 
given to new approaches which can extend dosage form retention time or can be 
engineered to deliver complex molecules such as proteins and peptides. The review 
will also provide a link between the physiology and local environment of the oral 
cavity in vivo and how this relates the performance of transmucosal delivery systems
5
. 
Agheranikunj Jamnadas et al. (2012) Oral mucosal drug delivery is an alternative 
method of systemic drug delivery that offers several advantages over both injectable 
and enteral methods. Because the oral mucosa is highly vascularised, drugs that are 
absorbed through the oral mucosa directly enter the systemic circulation, bypassing 
the gastrointestinal tract and first-pass metabolism in the liver. For some drugs, this 
outcome in rapid onset of action via a more easy and convenient delivery route than 
the intravenous site. How ever, can be administered through the oral mucosa because 
of the characteristics of the oral mucosa and the physicochemical properties of the 
drug
6
. 
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N.Nishan et al. (2013) Bioadhesion can be defined as a phenomenon of interfacial 
molecular attractive forces in the midst of the surfaces of biological substrate and the 
natural or synthetic polymers, which allows the polymer to adhere to biological 
surface for an extended period of time. The buccal region is an offers adorable route 
of administration drugs for systemic delivery. Among the various transmucosal sites 
available, mucosa of the buccal cavity was found to be the most convenient and easily 
approachable site for the delivery of therapeutic agents for both local and systemic 
delivery retentive dosage form. Because buccal drug delivery system prolong the 
residence time of dosage form at the site
7
. 
Amit Kumar Bind et al. (2013) Drug delivery via the oral mucous membrane is 
considered to be a promising alternative to the oral route. Sublingual route is a rapid 
onset of action and better patient compliance than orally ingested tablets. Sublingual 
literally meaning is “under the tongue”, administrating substance via mouth in such a 
way that the substance is rapidly absorbed via blood vessels under tongue. The 
portion of drug absorbed through the sublingual blood vessels bypasses the hepatic 
first‐pass metabolic processes giving acceptable bioavailability. Different techniques 
are used to formulate the sublingual dosage forms
8
. 
Kamal Saroha et al. (2008) Mucoadhesive drug delivery system prolong the 
residence time of the dosage form at the site of application or absorption and facilitate 
an intimate contact of the dosage form with the underline absorption surface and thus 
contribute to improved and better therapeutic performance of the drug. The 
bioadhesive polymers that adhere to the mucin/epithelial surface are effective and 
lead to overcome the relatively short gastrointestinal (GI) time and improve 
localization for oral controlled or sustained release drug delivery systems 
improvement in oral drug delivery. Improvements are also expected for other mucus-
covered sites of drug administration. Bioadhesive polymers find application in the 
eye, nose, and vaginal cavity as well as in the GI tract, including the buccal cavity and 
rectum
9
. 
Debjit Bhowmik et al. (2009) Fast- or mouth dissolving tablets have been formulated 
for pediatric, geriatric, and bedridden patients and for active patients who are busy 
and traveling and may not have access to water. The formulations gives an 
opportunity for product line extension in the Many difficulties in taking conventional 
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oral dosage forms (solutions, suspensions, tablets, and capsules) because of hand 
tremors and dysphagia. Oral route problems also are common in young persons 
because of their underdeveloped muscular and nervous systems
10
.  
K.patel Nibha et al. (2012) Oral mucosal drug delivery is an alternative and 
promising method of systemic drug delivery which offers several advantages. 
Sublingual literally meaning is ''under the tongue'', administrating substance via 
mouth in such a way that the substance is rapidly absorbed via blood vessels under 
tongue. Sublingual route offers advantages such as bypasses hepatic first pass 
metabolic process which gives improved bioavailability, rapid onset of action, patient 
fulfillment, self-medicated. Dysphasia (difficulty in swallowing) is common amid in 
all ages of people and more in pediatric, geriatric, psychiatric patients. In terms of 
permeability, sublingual area of oral cavity is more permeable than buccal area which 
is in turn is more permeable than palatal area
11
. 
PriyankPatel et al. (2010) Drug delivery via sublingual mucous membrane is 
considered to be a promising alternative to the oral route. This route is useful when 
rapid onset of action is desired as in the case of anti emetics such as ondansetron. In 
terms of permeability, the sublingual area of the oral cavity is more permeable than 
cheek and palatal areas of mouth. The drug absorbed via sublingual blood vessels 
bypasses the hepatic first-pass metabolic processes giving acceptable bioavailability 
with low doses and hence decreases the side effects. Sublingual drug delivery system 
is convenient for pediatric, geriatric, and psychiatric patients with dysphagia
12
.  
F R sheeba et al. (2009) The aim of this study was to evaluate the effect of increasing 
nifedipine load on the characteristics of fast-disintegrating sublingual tablets for the 
potential emergency treatment of anginal pain and hypertension. Nifedipine 
undergoes first pass metabolism in liver and gut wall which has oral bioavailability of 
43-77%. Fast relieve anginal pain and hypertension, An attempt has been made to 
prepare fast dissolving tablets of nifedipine Sublingual dosage form bypasses the 
metabolism of the nifedipine in liver. Using super disintegrates like cros carmellose 
sodium, sodium starch glycolate, Crosspovidone. Three different groups of 
formulations (A, R, and V) with variation in tablet excipients were prepared by direct 
compression method
13
.  
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Sindhu Abraham et al. (2010) The objective of this research was to develop and 
optimize sublingual tablets of Rabeprazole Sodium, a class of Proton pump inhibitors 
which is effective in the treatment of acid peptic disorders. The tablets were prepared 
by wet granulation method based on a central composite design. The formulation 
variables included quantity of Crospovidone, (X1), and quantity of Croscarmellose 
Sodium (CCS), (X2), while the response variables determined were wetting time and 
In vitro dispersion time. A quadratic model was used to quantitatively evaluate the 
main effects and interaction. Surface response plots are presented, to graphically 
represent the effect of the independent variables on the wetting time and 
disintegration time. The hardness of all the formulations was in the range 3.0 – 4.0 
kg/cm2
14
.  
A.Naimish et al. (2013) Schizophrenia and schizoaffective disorder are severe and 
chronic psychiatric illnesses for which treatment compliance is important in the 
prevention of relapse. Atypical antipsychotic drugs, such as risperidone, have been 
found to be effective in the treatment of a range of psychiatric disorders. Sublingual 
tablet of oral formulations of these drugs have been developed to improve their 
acceptability to patients and thus improve compliance. Improve solubility, 
bioavailability and to achieved rapid onset action was focus of present investigation
15
. 
Gupta et al. (2010) In recent decades, a variety of pharmaceutical research has been 
conducted to develop new dosage forms. Among the dosage forms developed to 
facilitate ease of medication, the rapid disintegrating tablet (RDT) is one of the most 
widely employed commercial products. As our society is becoming increasingly aged, 
the development of Fast- or mouth dissolving tablets have been formulated for 
pediatric, geriatric, and bedridden patients and for active patients who are busy and 
traveling and may not have access to water. Such formulations provide an chance for 
product line addition in the many elderly persons will have difficulties in taking 
predictable oral dosage forms (viz., solutions, suspensions, tablets, and capsules) 
because of hand tremors and dysphagia. Swallowing problems also are common in 
young individuals because of their underdeveloped muscular and nervous systems
16
. 
H.Zhang et al. (2002) Oral mucosal delivery of sedatives such as midazolam, 
triazolam and etomidate has shown favorable results with clinical advantages over 
other routes of administration. Oral mucosal delivery of the anti nausea drugs 
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scopolamine and prochlorperazine has received some attention, as has oral mucosal 
delivery of drugs for erectile dysfunction. Oral transmucosal formulations of 
testosterone and estrogen have been developed. In clinical studies, sublingual 
testosterone has been shown to result in increases in lean muscle mass and muscle 
strength, improvement in positive mood parameters, and Oral mucosal drug delivery 
is an alternative method of systemic drug delivery that offers several advantages over 
both injectable and enteral methods. Because the oral mucosa is highly vascularised, 
drugs that are absorbed through the oral mucosa directly enter the systemic 
circulation, bypassing the gastrointestinal tract and first-pass metabolism in the 
liver
17
. 
David harries et al. (1992) The delivery of drugs via the mucous membranes lining 
the oral cavity. with consideration of both systemic delivery and local therapy ,the 
structure and composition of mucousa at different site in the oral cavity, factor 
affecting mucosal permeability, penetration enhancement,  selection of appropriate 
experimental systems for studying mucosal permeability ,and formulation factor 
relevant to the design of systems for oral mucosal delivery are discussed. The 
sublingual delivery gives raped absorption and good permeability this system is not 
suitable for sustained delivery systems. For this reason buccal mucosa is good for 
number of peptide drugs. It mainly low molecular weight, high potency. it is safe 
route for penetration enhancement and to delivery in systemic
18
.   
P.V Divya et al. (2006) Recently a new approach using local delivery systems 
containing antimicrobial has been introduced. This produces more constant and 
prolonged concentration profiles. Both topical delivery system and controlled release 
system have been termed as local delivery. The term local delivery and site-specific 
delivery are sometimes used synonymously. The potential therapeutic advantage of 
local delivery approach has been claimed to be several fold. Local delivery devices 
are systems designed to deliver agents locally into periodontal pocket but without any 
mechanism to retain therapeutic levels for a prolonged period of time
19
. 
Mitchell et al. (2009) This study examined cardiac patients knowledge and use of 
sublingual glycerylnitrate. A non-experimental, retrospective descriptive design with 
a convenience sampling strategy was used setting and  .participate were cardiac in 
patients  who were prescribed  sublingual glecerylnitrate  at the study hospital .main 
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outcome measure :participant knowledge and use was assessed using the sublingual 
nitroglycerine interview schedule Which is a valid and reliable tool. Findings 
indicates that patients have limited knowledge of and do not always appropriately 
used slats, particularly in terms of the way men transport the medication. There for 
there is needed to develop and improvement educational strategies to feciliy Tate 
greater self management of angina
20
. 
H. Kazerani et al. (2009) This study aimed to evaluate the response rate, clinical 
efficacy and onset of action of sublingual captopril in patients diagnosed with 
hypertensive urgency. In this cross-sectional study (67 female and 34 male) patients 
with a diagnosis of hypertensive urgency (systolic pressure greater than or equal to 
180 mmHg and/or diastolic pressure greater than or equal to 110 mmHg, and no 
findings of target organ damage) was included. and blood pressure was measured 
during a follow-up period of 120 minutes. The Sublingual captopril (25 mg) was 
administered and blood pressure was measured during a follow-up period of 120 
minutes, Sublingual captopril can be used as an successful, simply applicable and safe 
treatment and management of hypertensive need for 120 minutes for those who do not 
get multidrug antihypertensive regimens
22
. 
DN John et al. (1992) The pharmacokinetics and pharmacodynamics of verapamil 
administered via the oral and sublingual routes were compared in a randomized, two-
way cross-over study involving six healthy male volunteers. Administered 
sublingually, a verapamil 40 mg crushed tablet produced a significantly higher peak 
plasma concentration, a greater rate of absorption, and greater bioavailability when 
compared with orally administered verapamil. In comparison with oral dosing, PR 
intervals were significantly (P less than 0.05) prolonged between 30 and 90 min after 
sublingual verapamil dosing. Correlations between log plasma verapamil 
concentration and percentage increase in PR interval were greater after sublingual 
compared with oral dosing in all volunteers
23
. 
Tine W. Hansen et al. (2010) Circadian profile of systolic BP. We analyzed studies 
in hypertensive patients (n_23 856) separately from those in individuals randomly 
recruited from populations (n_9641). We pooled summary statistics and individual 
subject data, respectively. In both patients and populations, in analyses in which night 
time BP was additionally adjusted for day time BP. With adjustment for the 24-hour 
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BP, both the night-to-day BP ratio and dipping status remained significant predictors 
of outcome but added little prognostic value over and beyond the 24-hour BP level. In 
the absence of conclusive evidence proving that non dipping is a reversible risk factor, 
the option whether or not to restore the diurnal blood pressure profile to a normal 
pattern should be Current guidelines on the interpretation of ambulatory BP recording 
need to be updated
23
. 
A.V Chobanian et al. (2003) The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure” provides a 
new guideline for hypertension prevention and management. The following are the 
key messages: (1) In persons older than 50 years, systolic blood pressure (BP) of 
more than 140 mm Hg is a much more important cardiovascular disease (CVD) risk 
factor than diastolic BP; (2) The risk of CVD, beginning at 115/75 mm Hg, doubles 
with each increment of 20/10 mm Hg; individuals who are   at 55 years of age have a 
90% lifetime risk for developing hypertension; (3) Individuals with a systolic BP of 
120 to 139 mm Hg or a diastolic BP of 80 to 89 mm Hg
24
. 
Mulrow et al. (1995) Trends in prevalence, awareness, treatment, and control of 
hypertension in the adult US population are reported. The data are from the National 
Health and Nutrition Examination Surveys (NHANES) carried out in four separate 
surveys, the last being NHANES III 1988-1991. Age adjusted prevalence of 
hypertension at (160/95) mm Hg declined from 20% to 14%, and at ( 140/90 mm Hg 
declined from 36.3% to 20.4% in NHANES III. Hypertension awareness increased 
significantly to as high as 89% for those with blood pressures (160/95). For all people 
with blood pressure ( 160/95 nearly 64% have it controlled below that level, but only 
29% have their blood pressure controlled below 140/90. Although the data from these 
surveys are encouraging, there are still too many people in the USA with uncontrolled 
hypertension
25
. 
Aim and Objective
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3. AIM AND OBJECTIVE 
Difficulty in swallowing (dysphagia) is a common problem of all age groups, 
especially the elderly and pediatrics, because of physiological changes associated with 
these groups. Other categories that experience problems using conventional oral 
dosage forms include are the mentally ill, uncooperative and nauseated patients, those 
with condition of motion sickness, sudden episodes of allergic attack or coughing.  
Sometimes it may be difficult to swallow conventional products due to 
unavailability of water. These problems led to the development of a novel type of solid 
dosage form called sublingual tablets, which disintegrate and dissolve rapidly in saliva 
without the need of drinking water. They are also known as fast dissolving tablets, 
melt-in-mouth tablets, rapimelts, porous tablets, orodispersible tablets, quick 
dissolving tablets or rapidly disintegrating tablets. Upon ingestion, the saliva serves to 
rapidly dissolve the dosage form.  
The saliva containing the dissolved or dispersed medicament is then swallowed 
and the drug is absorbed in the normal way. Some drugs are absorbed from the mouth, 
pharynx, and oesophagus as the saliva passes down into the stomach. In these cases, 
the bioavailability of drugs is significantly greater than those observed from 
conventional dosage forms. 
Aim of the work: 
In the present work an attempt will be made to formulate nimodipine sublingual 
tablets, using different superdisintegrants for treatment of hypertension, the fast 
dissolving tablet provides a rapid onset of action. 
The objectives of the work: 
1. To design the formula for sublingual tablet. 
2. To selected model drug and develop formula and prepare tablets. 
3. To evaluate the formulated tablets.  
4. To study the in-vitro dissolution profile of prepared tablets. 
5. To carry out stability studies of the selected formulations. 
 
Plan of work
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4. PLAN OF WORK 
 Literature survey 
 Preformulation  studies with physicochemical parameters: 
 
API characterization 
 Solubility  
 Bulk density 
 Tapped density 
 Angle of repose 
 Compressibility index 
 Hausner’s ratio 
 Drug excipient compatibility study 
 
Physical Evaluation of blend 
 Bulk density 
 Tapped density 
 Angle of repose 
 Compressibility index 
 Hausner’s ratio 
 
Evaluation of tablets 
 Hardness 
 Uniformity of thickness 
 Friability 
 Weight variation 
 Content uniformity 
 Disintegration  
 Wetting time 
 In vitro dissolution studies 
 Drug release kinetics. 
Drug and excipients profile
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5. DRUG PROFILE 
5.1. Drug profile 
Nimodipine belongs to the class of pharmacological agents known as calcium 
channel blockers.  
Structure:  
 
 
 
 
 
CHEMISTRY
 
IUPAC Name : Isopropyl 2 – methoxyethyl 1, 4 - dihydro - 2, 6 - dimethyl - 4 
- (m-nitrophenyl) - 3, 5 - pyridinedicarboxylate 
Empirical Formula : C21H26N2O7. 
Molecular Weight : 418.5 
Melting Point  : 118

C to 122

C 
Solubility   : Practically insoluble in water. 
PHYSICAL PROPERTIES 
Nature : Nimodipine is a yellow crystalline nature. 
Storage : Store in a well-closed container, protected from light. Store at                                            
25°C (77°F). 
CLINICAL PHARMACOLOGY: 
Mechanism of Action:  
 Nimodipine is a calcium channel blocker. The contractions of smooth muscle 
are dependent upon calcium ions. Nimodipine inhibits calcium ion transfer into these 
cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, 
Nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the 
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body perhaps because it is highly lipophilic, allowing it to cross the blood-brain 
barrier; concentrations of nimodipine as high as12.5 ng/mL have been detected in the 
cerebrospinal fluid of nimodipine-treated  subarachnoid hemorrhage (SAH) patients. 
The precise mechanism of action of nimodipine in humans is unknown. Although the 
clinical studies described below demonstrate a favorable effect of nimodipine on the 
severity of neurological deficits caused by cerebral vasospasm following SAH, there 
is no arteriographic evidence that the drug either prevents or relieves the spasm of 
these arteries. 
Pharmacokinetics and Metabolism:  
 In man, nimodipine is rapidly absorbed after oral administration, and peak 
concentrations are generally attained within one hour. There were no signs of 
accumulation when Nimodipine was given three times a day for seven days. 
Nimodipine is over 95% bound to plasma proteins. The binding was concentration 
independent over the range of 10 mg/mL to 10 µg/mL. Nimodipine is eliminated 
almost exclusively in the form of metabolites and less than 1% is recovered in the 
urine as unchanged drug. Because of a high first-pass metabolism, the bioavailability 
of nimodipine averages 13% after oral administration. The bioavailability is 
significantly increased in patients with hepatic cirrhosis, with Cmax approximately 
double that in normal’s which necessitates lowering the dose in this group of patients . 
In a study of 24 healthy male volunteers, administration of Nimodipine capsules 
following  a standard breakfast resulted in a 68% lower peak plasma concentration 
and 38% lower bioavailability relative to dose under fast conditions. 
In a single parallel-group study involving 24 aged subjects (aged 59–79) and 24 
younger subjects (aged 22–40), the experimental AUC and Cmax of nimodipine was 
approximately 2-fold higher in the old peoples compared to the younger study 
subjects following oral administration (given as a single dose of 30 mg and dosed to 
steady state with 30 mg t.i.d. for 6 days). 
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EXCIPIENT PROFILE 
5.2. CROSSCARMELLOSE SODIUM 
Synonyms: 
Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; Explocel; modified cellulose 
gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol. 
Chemical Name: 
Cellulose, carboxymethyl ether, sodium salt, crosslinked  
 Structural Formula: 
 
 
 
  
 
Empirical Formula: 
Croscarmellose sodium is a crosslinked polymer of carboxymethylcellulose sodium. 
Functional Category: 
Tablet and capsule disintegrant. 
Applications in Pharmaceutical Formulation or Technology: 
In tablet formulations, croscarmellose sodium may be used in both direct-compression 
and wet-granulation processes. The crosscarmellose sodium when used in wet 
granulation added in both the dry and wet stages of process so that the penetrability 
and swelling capability of the disintegrant is best utilized. Croscarmellose sodium at 
concentrations up to 5% w/w may be used as a tablet disintegrant, although normally 
2% w/w is used in tablets prepared by direct compression and 3% w/w in tablets 
prepared by a wet-granulation process.  
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Uses of croscarmellose sodium. 
Use Concentration (%) 
Disintegrant in capsules 10–25 
Disintegrant in tablets 0.5–5.0 
 Description: 
Cross carmellose sodium occurs as an odorless, white or grayish-white powder. 
 Stability and Storage Conditions: 
 Cross carmellose sodium is a stable though hygroscopic material.A model 
tablet formulation prepared by direct compression, with cross carmellose sodium as a 
disintegrant, showed no significant difference in drug dissolution after storage at 30°C 
for 14 months. Cross carmellose sodium should be stored in a well-closed container in 
a cool, dry place. 
 Incompatibilities: 
 The efficacy of disintegrants, such as cross carmellose sodium, may be slightly 
reduced in tablet formulations prepared by either the wet-granulation or direct-
compression process that contain hygroscopic excipients such as sorbitol. 
Cross carmellose sodium is not compatible with strong acids or with soluble salts of 
iron and some other metals such as aluminum, mercury, and zinc. 
 Safety   : 
 Cross carmellose sodium is mainly used as a disintegrant in oral 
pharmaceutical formulations and is generally regarded as an essentially nontoxic and 
nonirritant material. However, oral consumption of large amounts of cross carmellose 
sodium may have a laxative effect, although the quantities used in solid dosage 
formulations are unlikely to cause such problems. 
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5.3. Crospovidone 
Synonyms: 
Crosslinked povidone, E1202, Colliding CL, Colliding CL-M, Polyplasdone XL, 
Polyplasdone XL-10, polyvinylpolypyrrolidone, PVPP, and 1-vinyl-2-pyrrolidinone 
homopolymer. 
 Chemical Name: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Empirical Formula and Molecular Weight: 
(C6H9NO)n>1 000 000 
An exact determination of the molecular weight has not been established because of 
the insolubility of the material. 
 Structural Formula: 
 
 
 
 
 Functional Category: 
Tablet disintegrant 
Applications in Pharmaceutical Formulation or Technology: 
Cross povidone is a water-insoluble tablet disintegrant and dissolution agent 
used at 2–5% concentration in tablets prepared by direct-compression or wet- and dry-
granulation methods. It rapidly exhibits high capillary activity and pronounced 
hydration capacity, with little tendency to form gels. Studies suggest that the particle 
size of cross povidone strongly influences disintegration of analgesic tablets. Larger 
particles provide a faster disintegration than smaller particles. It also used in solubility 
improving. With the technique of co-evaporation, cross povidone can be used to 
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enhance the solubility of poorly soluble drugs. The drug is adsorbed on to cross 
povidone in the presence of a suitable solvent and the solvent is then evaporated. This 
technique results in faster dissolution rate. 
 Description: 
Cross povidone is a white to creamy-white, finely divided, free-flowing, 
practically tasteless, odorless, and hygroscopic powder. 
 Stability and Storage Conditions: 
Crosspovidone is hygroscopic; it should be stored in a cold, dry, airtight 
container. 
5.4. Sodium starch glycollate 
Synonym: 
Carboxymethyl starch, sodium salt; carboxymethylamylum natricum; Explosol; 
Explotab; Glycolys; Primojel; starch carboxymethylether, sodium salt; Tablo; Vivastar  
Chemical name: 
Sodium carboxymethyl starch 
Structural formula: 
 
 
 
 
 
Empirical formula: 
Sodium salt of carboxymethyl ether of starch 
Molecular weight: 500000-1000000 g/mol 
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Functional category: 
Tablet and capsule disintegrant. 
Application in pharmaceutical technology: 
 Sodium starch glycolate is widely used in oral pharmaceuticals as disintegrant 
in capsule (1–6) and tablet formulations. It is commonly used in tablets prepared by 
either direct compression or wet-granulation processes. The usual concentration 
employed in a formulation is between 2% and 8%, with the optimum concentration 
about 4%, although in many cases 2% is sufficient. rapid uptake of water followed by 
rapid enlargement and disintegration. Although the effectiveness of many disintegrants 
is affected by the presence of hydrophobic excipients such as lubricants, the 
disintegrant efficiency of sodium starch glycolate is unimpaired. Increasing the tablet 
compression pressure also appears to have no effect on disintegration time. Sodium 
starch glycolate has also been investigated for use as a suspending vehicle. 
 
5.5. Microcrystalline cellulose                                 
Synonyms: 
Avicel PH, Celex, Cellulose gel, Celphere, Ceolus KG, crystalline cellulose. 
Functional Category: 
 Adsorbent, suspending agent, tablet and capsule diluent, tablet disintegrant. 
Applications: 
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. In addition to its use as a binder/diluent, 
microcrystalline cellulose also has some lubricant and disintegrant properties that 
make it useful in tableting. 
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5.6. Magnesium stearate 
 Nonproprietary Names: 
BP: Magnesium Stearate 
JP: Magnesium Stearate 
PhEur: Magnesium Stearate 
USP-NF: Magnesium Stearate 
Synonyms: 
Dibasic magnesium stearate; magnesium distearate; magnesia stearas; magnesium 
octadecanoate; octadecanoic acid, magnesium salt; stearic acid, magnesium salt; 
Synpro 90. 
 
 Empirical Formula: C36H70MgO4 
Molecular Weight:  591.24 
The USP32–NF27 describes magnesium stearate as a compound of magnesium with a 
mixture of solid organic acids that consists chiefly of variable proportions of 
magnesium stearate and 
magnesium palmitate (C32H62MgO4). The PhEur 6.5 describes magnesium stearate 
as a mixture of solid organic acids consisting mainly of variable proportions of 
magnesium stearate and magnesium palmitate obtained from sources of vegetable or 
animal origin. 
Structural Formula: [CH3(CH2)16COO]2Mg 
Functional Category: Tablet and capsule lubricant. 
Uses in Pharmaceutical Formulation Technology: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is mainly used as a lubricant in capsule and tablet produce at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
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5.7. Mannitol 
 Nonproprietary Names: 
BP: Mannitol 
JP: D-Mannitol 
PhEur: Mannitol 
USP: Mannitol 
Synonyms: 
Cordycepic acid; C*PharmMannidex; E421; Emprove; manna sugar; D-mannite; 
mannite; mannitolum; Mannogem; Pearlitol. 
 
Chemical Names and CAS Registry Number: 
D-Mannitol [69-65-8] 
 
Molecular Formula : C6H14O6 
Molecular Weight: 182.17 
 
Structural Formula: 
 
 
 
 
 
 
 Functional Category: 
 
Diluent; plasticizer; sweetening agent; tablet and capsule diluent; therapeutic agent; 
tonicity agent. 
 
Applications in Formulation Pharmaceutical Technology: 
 Mannitol is widely used in pharmaceutical formulations and food products. In 
pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in 
tablet formulations, where it is of due to not hygroscopic it use in moisture 
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sensitive active ingredients.  Mannitol may be used in direct-compression tablet 
applications, for which the granular and spray-dried forms are available, or in wet 
granulations.  
 Granulations containing mannitol have the advantage of being dried easily. 
Specific tablet applications include antacid preparations, glyceryl trinitrate 
tablets, and vitamin preparations.  
 Mannitol is commonly used as an excipient in the manufacture of chewable tablet 
formulations because of its negative heat of solution, sweetness, and ‘mouth 
feel’. In lyophilized preparations, mannitol (20–90% w/w) has been included as a 
carrier to produce a stiff, homogeneous cake that improves the appearance of the 
lyophilized plug in a vial.  
 A pyrogen-free form is available specifically for this use. Mannitol has also been 
used to prevent thickening in aqueous antacid suspensions of aluminum 
hydroxide (<7% w/v). It has been suggested as a plasticizer in soft-gelatin 
capsules, as a component of sustained-release tablet formulations, and as a carrier 
in dry powder inhalers.  
 It is also used as a diluent in rapidly 424 Mannitol dispersing oral dosage forms. 
Used as a bulking agent and application in food.  
 Therapeutically, mannitol administered parenterally is used as an osmotic 
diuretic, as a diagnostic agent for kidney function, as an adjunct in the treatment 
of acute renal failure, and as an agent to reduce intracranial pressure, treat 
cerebral edema, and reduce intraocular pressure.  
 Given orally, mannitol is not absorbed significantly from the gastrointestinal 
tract, but in large doses it can cause osmotic diarrhea. 
 
5.8. TALC 
 Nonproprietary Names: 
BP: Purified Talc 
JP: Talc 
PhEur: Talc 
USP: Talc 
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 Synonyms: 
 
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Imperial; Luzenac Pharma; magnesium hydrogen metasilicate; MagsilOsmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore; talcum. 
 
 Chemical Names and CAS Registry Number: Talc [14807-96-6] 
 
Molecular Formula : Mg6(Si2O5)4(OH)4. 
 It may having small, variable amounts of  iron and aluminum silicate 
 
Functional Category: 
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant. 
 
Applications in Pharmaceutical Formulation or Technology: 
 Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent,  although today it is less commonly used.  
 However, it is widely used as a dissolution retardant in the development of 
controlled-release products. 
 Talc is also used as a lubricant in tablet formulations; in a novel powder 
coating for extended-release pellets; and as an adsorbant. 
 In topical preparations, talc is used as a dusting powder, although it should not 
be used to dust surgical gloves.  
 Talc is a natural it may therefore normally have microorganisms and should be 
sterilized when used as a dusting powder.  
 Talc is additionally used to clarify liquids and is also used in cosmetics and 
food products, mainly for its lubricant properties. 
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5.9. ASPARTAME 
 Nonproprietary Names: 
 
BP: Aspartame 
PhEur: Aspartame 
USP-NF: Aspartame 
 
 Synonyms: 
 
(3S)-3-Amino-4-[[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-4-oxobutanoic 
acid; 3-amino-N-(a carboxyphenethyl)succinamic acid N-methyl ester; 3-amino-N-(a-
methoxycarbonylphenethyl)-succinamic acid; APM; aspartamum; 
aspartylphenylamine methyl ester; Canderel; E951; Equal; methyl N-L-a-aspartyl-L-
phenylalaninate; NatraTaste; NutraSweet; Pal Sweet; Pal Sweet Diet; Sanecta; 
SC-18862; Tri-Sweet. 
 
Empirical Formula : C14H18N2O5 
 Molecular Weight: 294.30 
 
 Structural Formula: 
 
 
 
 
 
 
 
 
 
 
Functional Category: Sweetening agent. 
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Applications in Pharmaceutical Formulation Technology: 
 
 Aspartame is used as an intense sweetening agent in beverage products, food 
products, and table-top sweeteners, and in pharmaceutical preparations including 
tablets, powder mixes, and vitamin preparations.  
 It enhances flavor systems and can be used to mask some unpleasant taste 
characteristics; the approximate sweetening power is 180–200 times that of 
sucrose.  
 Unlike some other intense sweeteners, aspartame is metabolized in the body and 
consequently has some nutritive value: 1 g provides 17 kj (4 kcal) 
 
Materials & Equipments
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6. MATERIALS AND EQUIPMENTS 
 
Table No. 2: List of materials used with suppliers  
S. No. Materials Supplier 
1. Model  Drug Natco pharmaceuticals, Hyderabad 
2. Mannitol Drug India Pvt.Ltd, Guwahati 
3. MCC 101 Drug India Pvt.Ltd, Guwahati 
4. Crosscarmellose sodium Drug India Pvt.Ltd, Guwahati 
5. Crospovidone Drug India Pvt.Ltd, Guwahati 
6. SSG Drug India Pvt.Ltd, Guwahati 
7. Talc Drug India Pvt.Ltd, Guwahati 
8. Aspartame Drug India Pvt.Ltd, Guwahati 
9. Magnesium stearate Drug India Pvt.Ltd, Guwahati 
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Table No. 3: List of equipments used 
S. No. Equipments Manufacturer 
1. Electronic Weighing Balance Sartorius BSA 224S – CW. 
2. Hardness Tester CINTEX Monsanto tester, Mumbai. 
3. UV- Spectrophotometer Shimadzu, Model No. UV-2450. 
4. Friability Test Apparatus Electro lab EF-2. 
5. Hot air oven Bio-tech India. 
6. Bulk Density Apparatus Electro lab EF-2. 
7. Tablet Compression Machine CADMACH, Ahmadabad. 
8. Tablet Dissolution Tester TDT-08L (USP), Electro lab. 
9. Ultra solicitor bath Bio-tech India. 
10. Digital pH meter Microprocessor pH stat/Analyzer. 
11. FTIR  Spectrophotometer IR Affinity-1, Shimadzu. 
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Department Of Pharmaceutics                                                                    Methodology 
 
Annai Veilankanni’s Pharmacy College,Chennai   39 
 
7. METHODOLOGY 
 PREPARATION OF STANDARD GRAPH  
7.1. Preparation of Stock solution with Distilled water 
100mg of the drug was accurately weighed and transferred into the 100 ml 
volumetric flask. It was dissolved in sufficient quantity of methanol and volume was 
made up to the mark with methanol to get a 1000 µg/ml solution. This was the 
standard stock solution containing 1 mg/ml of model drug (Stock 1).  
 UV Absorption Maxima (λmax) of drug sample in water 
One ml of the above solution was then further diluted to 100 ml with water to 
get a stock solution of 10 (µg/ml). UV scanning was done for 10 µg/ml drug solution 
from 200-400 nm using methanol as a blank in schimadzu, UV 1700 
spectrophotometer. The wavelength maximum was found to be at 250 nm. 
 Preparation of  the calibration curve  
From the stock solution 2, 4, 6, 8, 10 and 12 ml were transferred to 10 ml 
volumetric flasks and were diluted with the water, up to the mark to obtain 
concentration of2, 4, 6, 8, 10 and 12µg/ml respectively. Absorbance of each solution 
was measured at 226 nm.  The Standard curve preparation was performed in triplicate. 
The absorbance was plotted against the concentrations and the graph with the straight 
line equation and r
2
 value were obtained. 
7.1.1. Preparation of Stock solution with 6.8 PH Phosphate Buffer 
100mg of the drug was accurately weighed and transferred into the 100 ml 
volumetric flask. It was dissolved in sufficient quantity of phosphate buffer and 
volume was made up to the mark with methanol to get a 1000 µg/ml solution. This was 
the standard stock solution containing 1 mg/ml of model drug.(Stock 1).  
 UV Absorption Maxima (λmax) of drug sample in 6.8 PH Phosphate Buffer 
One ml of the above solution was then further diluted to 100 ml with phosphate 
buffer to get a stock solution of 10 (µg/ml). UV scanning was done for 10 µg/ml drug 
solution from 200-400 nm using methanol as a blank in schimadzu, UV 1700 
spectrophotometer. The wavelength maximum was found to be at 250 nm. 
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 Preparation of  the calibration curve 
From the stock solution 2, 4, 6, 8, 10 and 12 ml were transferred to 10 ml 
volumetric flasks and were diluted with the phosphate buffer, up to the mark to obtain 
concentration of 2, 4, 6, 8, 10 and 12µg/ml respectively.  Absorbance of each solution 
was measured at 250 nm.  The Standard curve preparation was performed in triplicate. 
The absorbance was plotted against the concentrations and the graph with the straight 
line equation and r
2
 value were obtained. 
7.2. FT-1R Studies 
The IR absorption spectra of the NMD drug and with different 
superdisintegrants, were taken in the range of 4000-450 cm-1 using KBr disc method, 
1-2 mg of the substance to be examined was triturated with 300-400 mg, specified 
quantity, of finely powered and dried potassium bromide .These quantities are usually 
sufficient to give a disc of 10-15mm diameter and pellet of suitable intensity by a 
hydraulic press. The scans were evaluated for presence of principle peaks of drug, 
shifting and masking of drug peaks due presence superdisintegrants. 
Table No. 4: Drug excipient compatibility study protocol 
Sl. No. Name of the substance D:E ratio 
1 Model Drug (API) 1:0 
2 API + Mannitol 1:2 
3 API + MCC 1:2 
4 API + crosscarmellose sodium 1:2 
5 API + crosspovidone 1:2 
6. API + Sodium starch glycollate 1:2 
7. API +Magnesium stearate 1:2 
Note: D: E – Drug : Excipient   
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7.3. Preformulation parameters 
Pre formulation testing is defined as investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. It gives 
information needed to define the nature of the drug substance and provide frame work 
for the drug combination with pharmaceutical excipients in the dosage form. 
 
Bulk Density: 
Apparent bulk density was determined by pouring presieved drug excipient 
blend into a graduated cylinder and measuring the volume and weight “as it is”. It is 
represent in gm/mL and is given by 
D b = M/V0 
Where, M  mass of powder, 
V0 Bulk volume of the powder 
 
 Tapped Density: 
It was determined by placing a graduated cylinder, containing a known mass 
of drug- excipient blend, on mechanical tapping apparatus. Take the powder to 
constant volume The tapped volume was measured by tapping. It expressed in gm/mL 
and is given by 
Dt = M / Vt 
Where, M is the mass of powder, 
Vt is the tapped volume of the powder
18,19
. 
 
 Carr’s index: 
It is expressed in percentage and is expressed by 
I = Dt - Db/Dt 
Where, Dt is the tapped density of the powder 
Db is the bulk density of the powder
20, 21
. 
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Table No. 5: Relationship between % Compressibility and Flow-ability 
% Compressibility Flow-ability 
5-15 Excellent 
1-16 Good 
18-21 Fairly Acceptable 
23-35 Poor 
33-38 Very poor 
<40 Very very poor 
 
 
Hausner’s ratio: 
Hausner ratio is an indirect index of ease of powder flow. It is calculated by 
the following formula. 
H= Dt / Db 
Where, Dt is the tapped density of the powder 
Db is the bulk density of the powder. 
 Lower hausner ratio (< 1.25) indicate better flow properties than higher ones 
(>1.25)
18,19
. 
Angle of Repose: 
The frictional forces of a loose powder can be measured by using angle of 
repose. It is an indicative of the flow properties of the powder. It is defined as 
maximum angle possible between the surface of the pile of powder and the horizontal 
plane. 
tan (θ) = h / r 
                                              θ = tan-1 (h / r) 
Where, 
θ is the angle of repose. 
h is the height in cms 
r is the radius in cms. 
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The powder mixture was allowed to flow through the funnel fixed to a stand at 
definite height (h). Angle of repose was calculated by measuring the tallness and 
radius of the heap of powder formed. Care was taken to see that the powder particles 
slip and roll over each other through the sides of the funnel. Relationship between 
angle of repose and powder flow property
22,23
. 
 
Table No. 6: Angle of repose as an indication of powder flow properties 
 
Angle of repose Flow 
<25 Excellent 
25 – 30 Good 
30 – 40 Passable 
>40 Very poor 
 
7.4. Formulation development  
Sublingual tablets containing 30 mg of model drug were prepared with a total 
tablet weight of 200mg. Considering the preformulation studies and the literature 
survey conducted the excipients were selected and an attempt to produce sublingual 
tablets with ideal mouth feel maintaining the basic tablet properties was made. 
 Selection of superdisintegrants: 
Short disintegration time with good dispersability is the most important 
characteristics of a sublingual or mouth dispersible tablets. The necessity of a 
Sublingual tablet is to disintegrate within seconds, in limited amount of the water 
available in the form of saliva. Different superdisintegrants croscarmellose sodium, 
crosspovidone, Sodium starch glycol late in the concentration range of 1.5% to 6% 
were used which act as disintegrates used at various concentrations and a comparative 
study was carried out. 
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 Selection of diluents 
Since direct compression method was followed the choice of directly 
compressible diluents was important. Microcrystalline cellulose was selected as the 
filler or diluents owing to its multiple functionality as binder, disintegrant, 
compressibility and flowability. Of the various grades available the granular form 
Avicel PH102 was selected as it had been already reported to provide lower crushing 
strengths and shorter disintegration times.  
Mannitol  was selected to produce a cooling and pleasant mouth feel, it was reported* 
that mannitol above the concentration of 33% gives good mouth feel, thus mannitol in 
all the batches was fixed at a concentration of 40-47%. Besides mannitol also 
possesses sweetening properties and reduces the gritty mouth feel effect due to 
microcrystalline cellulose. It also has good compressibility properties and solubility in 
water. 
 Selection of  additional ingredients 
The flow property of the pure drug was found to be moderate (Hauser’s ratio ~ 
1.4) thus to still improve the flow of the blend magnesium stearate (2.5%  to 4%) as 
lubricant were incorporated also magnesium stearate decreases the hardness of tablets 
without affecting the disintegration time. Aspartame was used in the concentration of 
2.5% to 6% as the sweetener. 
7.4.1. Formula 
 Sublingual tablets of model drug was formulated using mannitol, Avicel 
pH102 (microcrystalline cellulose)  as diluents. Sublingual tablet was prepared by 
direct compression technique as it’s a cost effective method. Superdisintegrants used 
are Crosspovidone, Crosscarmellose sodium, Sodium starch glycol late, disintegrant 
sodium CMC. Aspartame as sweetening agent. Magnesium stearate (3% to 4%) as 
lubricant. 
7.4.2. Formulation of different batches 
      The main aim of the present study was to formulate different batches using 
three various superdisintegrants and other ingredients in varying concentrations. So 
different batches of formulations was planned accordingly. According to that F1, F2, 
F3(with Crosspovidone 1.5%, 3%, 6%),  F4, F5, F6(with Crosscarmellose 1.5%, 3%, 
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6%)and F7, F8, F9(with Sodium starch glycol late 1.5%, 3%, 6%).The slight bitter 
taste of the drug was masked using aspartame (2.5% to 6%) as the sweetening agent.     
 7.4.3. Method of formulation 
1. Direct compression method. 
 The model drug (NMD) is thoroughly mixed with the superdisintegrants, and 
then other excipients are added to the mixer and passed through the sieve (#:40). 
Collect the powder mixer, blend with magnesium stearate (pre sieved), and subject the 
blend for tablet compression. 
 Representation of Direct Compression Technique for design of Sublingual 
Tablets  
 The drug and the excipients were passed through sieve no: 40 except lubricant. 
The blend was further  lubricated with Magnesium stearate (#:60)  and the powder 
blend is subjected to drying for removal of moisture content  and was compressed by 
direct compression method by using  flat faced  punches in  CADMACH 16 punches  
tablet  punching machine. Round punches measuring 8.7mm diameter were used for 
compression. Tablet of 200mg was prepared by adjusting hardness and volume screw 
of compression machine properly 
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Table No. 7:  Formulations of different batches 
 Formulation Code 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Nimodipine 30 30 30 30 30 30 30 30 30 
Crosspovidone 3 6 12 - - - - - - 
Crosscarmellose 
sodium 
- - - 3 6 12 - - - 
SSG - - - - - - 3 6 12 
MCC 102 66 64 58 66 64 58 66 64 58 
Aspartame 10 10 10 10 10 10 10 10 10 
Mannitol 80 80 80 80 80 80 80 80 80 
Magnesium 
stearate 
6 6 6 6 6 6 6 6 6 
Talc 4 4 4 4 4 4 4 4 4 
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7.5. Evaluation of tablets 
Hardness test: 
 Using a Monsanto hardness tester the rigidity (hardness) of the tablet was 
determined
14. 
Friability: 
The friability of a sample of 20 tablets was measured using a Roche friabilator 
(Electrolab). 20 previously weighed tablets were rotated at 25 rpm for 4 min. The 
weight loss of the tablets before and after
15
 
Measurement was calculated using the following formula  
 
Percentage friability = Initial weight – Final weight x 100 
                           Initial weight 
Weight Variation: 
             It was performed as per the method given in the united state pharmacopoeia. 
Twenty tablets were selected randomly from each formulation, weighed individually 
and the average weight and % variation of weight was calculated.  
Tablet thickness: 
Tablet thickness is an important characteristic in reproducing appearance and 
also in counting by using filling equipment. Some filling equipment utilizes the 
identical thickness of the tablets as a counting mechanism. Ten tablets were taken and 
their thickness was recorded Vernier calipers using micrometer. 
Drug Content Uniformity: 
Selected twenty tablets randomly and powdered. A quantity of this powder 
corresponding to 200mg of model drug was dissolved in 100 ml of 6.8pH phosphate 
buffer, stirred for 15 min and filtered. The 1ml of filtrate was diluted with 100 ml with 
6.8pH phosphate buffer. Absorbance of this solution was measured at 250nm using 
6.8pH phosphate buffer as blank and content of drug was estimated
16
.  
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In- vitro Disintegration Time: 
Disintegration times for sublingual tablets were determined using USP tablet 
disintegration apparatus with saline phosphate buffer of pH 6.8 as medium. 
Maintained the medium temp at 37±2°. The time in minute taken for complete 
disintegration of the tablets with no palatable mass remaining in the apparatus was 
measured. 
Wetting Time:  
A piece of tissue paper folded twice was placed in a small Petri dish (ID = 6.5 
cm) containing 6 mL of simulated saliva pH, a tablet was put on the amaranth powder 
containing paper the time required for upper surface of the tablet for formation of pink 
color was measured. 
Water absorption ratio: 
For measuring water absorption ratio, the weight of the tablet before keeping in 
the petri dish is noted (Wb). The wetted form of tablet was taken from petridish and 
reweighed (Wa). The water absorption ratio (R) can be the determined according to the 
following equation. 
R= 100 x (Wa-Wb) / Wb 
In vitro dispersion time: 
In vitro dispersion time was measured by dropping a tablet in a measuring cylinder 
containing 6ml of pH 6.8 (simulated saliva fluid) .Tablets from each formulation were 
randomly selected and in vitro dispersion time is expressed in seconds. 
In vitro Dissolution studies: 
Dissolution of the tablet of each batch was carried out using USP XXIII 
dissolution type II apparatus (ELECTRO LAB) using paddles at 50 rpm. As per the 
official recommendation of IP 900ml of 6.8 pH of phosphate buffer used as dissolution 
medium  and the temperature of the medium was set at 37 ± 0.5 0C. 5 ml of sample 
was withdrawn at predetermined time interval of 2 .,4., 6., 8 and 10 min. And same 
volume of fresh medium was replaced. The withdrawn samples were analyzed by an 
UV spectrophotometer at 250 nm using buffer solution as blank solution. 
Department Of Pharmaceutics                                                                    Methodology 
 
Annai Veilankanni’s Pharmacy College,Chennai   49 
 
                   Table No. 8:  Summary of general dissolution conditions 
 
 
 
 
 
 
 
 
 
Large tablets approaching or exceeding one gram and containing relatively dense 
particles may produce a mound in the dissolution vessel, which can be prevented by 
using higher paddle speeds. These two situations expand the suitable range of stirring 
to 25-75 rpm.  
The USP 1 (basket) apparatus may have certain applications for sublingual but is used 
less frequently due to specific physical properties of tablets
17
. 
7.6. Drug release kinetics: 
  As a model independent approach, comparison of time taken for the given 
proportion of the active drug to be dissolved in the dissolution medium and figures 
such as T50 and T90 were calculated by taking the time points of 50% and 90% of the 
drug dissolved and another parameter dissolution efficiency (DE) suggested by Khan 
were employed. DE is defined as the area under the dissolution curve up to the time t 
expressed as a percentage of the area of the rectangle described by 100% dissolution 
in the same time.  
 Dissolution Efficiency (DE) =   100 
.
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Sl. No. Parameter Specifications 
1. Dissolution medium pH 6.8 phosphate buffer +0.5% 
2. Temperature 37±0.5c 
3. Rotation speed 50 rpm 
4. USP Type II Paddle 
5. Volume withdrawn 5 ml every 2 minutes 
6. max 250 nm 
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 Dissolution efficiency can have a range of values depending on the time interval 
chosen. In any case, constant time intervals should be chosen for comparison. For 
example, the index DE30 would relate to the dissolution of the drug from a 
particular formulation after 30 minutes could only be compared with DE30 of other 
formulations. As a model dependent approach, for describing the mechanism and 
also the release kinetics, dissolution data were fitted to popular release models, 
which have been described as follows: 
Zero order kinetics: 
       Dissolution of drug from a dosage form that do not disaggregate and 
release the drug slowly that is where the drug release rate is independent of its 
concentration can be represented as follows. 
  (
  
  
)         
Where, A0 is initial amount of drug in the dosage form, 
 At is the amount of drug in the dosage form at time‘t’, 
k0is the zero order release constant, 
 1-(At/A0) represents the fraction of drug dissolved at time‘t’ 
 Graphical representation of fraction of drug dissolved verses time will be linear. 
This relation can be used to determine the drug dissolution of various types of 
modified release dosage forms e.g. matrix tablets with low soluble drugs, coated 
forms etc. The dosage forms following this profile release the same amount of 
drug by unit time and it is the ideal method of drug release in order to achieve a 
prolonged pharmacological action. 
First order kinetics: 
             The first order kinetics was first applied for drug dissolution studies by 
Gibaldi and Feldman in 1967 and later by Wagner in 1969. In this case, the drug 
release rate is concentration dependent and this can be depicted in decimal 
logarithm as follows. 
           
   
     
 
      Where, Atis the amount of drug released at time‘t’,  
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 A0 is the initial amount of drug in the solution, 
 K1 is the first order release constant 
     Graphical representation of the decimal logarithm of percent drug remaining 
verses time will be linear. Example for the dosage form follows this profile such 
as those containing water soluble drug in a porous matrices release the drug that is 
proportional to the amount of drug released by unit time. 
Hixon-crowell cubth root model: 
               To evaluate the drug release with changes in the surface area and 
diameter of the particles, Hixon-Crowell in 1931 recognized that the particle 
regular area is proportional to the cubic root of its volume and designed an 
equation as follows. 
√   
  √  
       
Where, A0 is the initial amount of drug in the dosage form, 
 At is the remaining amount of drug in the dosage form at time’t’, 
 Ks is a constant incorporating the surface volume relation. 
     Graphical representation of cubic root of the unreleased fraction of the drug 
verses time will be linear if the equilibrium conditions are not reached and if the 
geometrical shape of the dosage form diminishes proportionally over time. This 
model is used by assuming that release rate is limited by the drug particles 
dissolution rate and not by the diffusion. 
Higuchi model: 
             Higuchi in 1961 developed a model to study the release of water soluble 
and low soluble drugs incorporated in semisolid and solid matrices. To study the 
dissolution from a planar system having a homogeneous matrix, the relation 
obtained as follows. 
  √[ (      )]
 
 
Where, A is the amount of drug released at time‘t’ per unit area,  
C is the initial drug concentration,  
Cs is the drug solubility in the matrix media, 
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D is the diffusivity of drug molecules in the matrix substance.  
In general, Higuchi model can be simplified as, 
      √ 
 
 
Where, KH is the Higuchi dissolution constant. 
Korsmeyer-peppas model: 
              In 1983, Korsmeyer developed a simple and semi-empiric model, when 
diffusion is the main drug release mechanism, relating the drug release to the 
elapsed time (t). 
  
  
⁄      
 Where, n is the diffusion exponent for the drug release, 
t is the release time, 
a is a constant incorporating geometrical characteristic of the dosage form, 
        At/   is the fraction of drug release 
 
Table No. 9: Effect of ‘n’ value on drug transport mechanism 
Release exponent (n) Drug transport mechanism 
 
 
 
 
 
 
n=0.5 
n=0.5 
Fickian diffusion 
0.5<n<1 Non- fickian diffusion 
n=1 Case II transport 
n>1 
 
Super case II transport 
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7.7. Stability Studies:    
            The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room 
temperature requires a long time. To avoid this undesirable delay, the principles of 
accelerated stability studies are adopted. 
ICH specifies the length of study and storage conditions.  
Long-Term Testing: 25
0
 C ± 2
0
 C / 60% RH ± 5% for 12 Months  
Accelerated Testing: 40
0
 C ± 2
0
 C /75% RH± 5% for 6 Months  
Stability studies were carried out at 40
0
C ± 2
0
C /75% RH ± 5% for all the 
formulations for a period of 3 months. 
 The selected formulations were closely packed in aluminium foils and then 
stored at 40
0
 C ± 2
0
 C /75% RH ± 5% in stability chamber for 3 months and 
evaluated for their physical appearance, drug content and in-vitro drug release 
studies at intervals of 1month. The shelf life period of the prepared buccal tablets is 
determined by using similarity factor. 
 
 
 
Results & Discussion
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8.RESULTS AND DISCUSSION 
8.1. Calibration curve of Nimodipine 
Table No. 10:Standard Calibration curve of Nimodipine with Distilled water 
 
 
Figure No.3:Standard Calibration curve of NMD with Distilled water 
R² = 0.9982 
y = 0.1009x + 0.0123 
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Concentration in mcg\ml 
Linearity 
S.No Concentration(mcg/ml) Absorbance 
1 0 0 
2 2 0.209 
3 4 0.432 
4 6 0.644 
5 8 0.809 
6 10 0.995 
7 12 1.233 
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     In the current investigation, analytical method obeyed beer-lamberts law in the 
concentration range of 2-12 µg/ml and it was suitable for the estimation of 
Nimodipine using Distilled water. The value of correlation coefficient (r) for the 
linear regression equation was found to be more than 0.99 which indicates a positive 
correlation between the concentration of drug and corresponding absorbance values. 
Table No. 11:Standard Calibration curve of NMD with 6.8pH phosphate buffer 
S.No. Concentration (mcg/ml) Absorbance 
1 0 0 
2 2 0.206 
3 4 0.398 
4 6 0.656 
5 8 0.842 
6 10 1.044 
7 12 1.235 
 
 
Figure No.4:Standard Calibration curve of NMD with 6.8pH phosphate buffer 
y = 0.104x + 0.0018 
R² = 0.9987 
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     In the current investigation, analytical method obeyed beer-lamberts law in the 
concentration range of 2-12 µg/ml and it was suitable for the estimation of nimodipine 
using phosphate buffer of pH 6.8. The value of correlation coefficient (r) for the linear 
regression equation was found to be more than 0.99 which indicates a positive 
correlation between the concentration of drug and corresponding absorbance values. 
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8.2. FTIR studies   
Table No. 12:FT-IR interpretations of pure drug and physical mixtures 
S.No 
Functional 
group 
Characteristic 
peaks 
Observed peaks 
Nimodipine 
Nimodipine : 
MCC 
Nimodipine : 
SSG 
Nimodipine : 
CCS 
Nimodipine : 
Crospovidone 
Nimodipine : 
Mannitol 
Nimodipine : 
Mg. stearate 
1 
C-H 
(Aromatic 
bending) 
680-860 cm
-1
 782.17 cm
-1 782.17 cm-1 781.20 cm-1 781.20 cm-1 782.17 cm-1 783.13 cm-1 782.12 cm-1 
2 
NO2 
(stretching) 
1300-1600 cm
-1
 1369.52 cm
-1 1368.55 cm-1 1369.52 cm-1 1369.52 cm-1 1369.52 cm-1 1369.52 cm-1 1369.52 cm-1 
3 
C=C 
(Aromatic 
stretching) 
1400-1600 cm
-1
 1465.96 cm
-1 1465.96 cm-1 1415.81 cm-1 1415.81 cm-1 1465.00 cm-1 1415.81 cm-1 1426.42 cm-1 
4 
N-H 
(bending) 
1580-1650 cm
-1
 1626.06 cm
-1
 1627.03 cm
-1
 1638.60 cm
-1
 1637.64 cm
-1
 1627.99 cm
-1
 1626.06 cm
-1
 1624.13 cm
-1
 
5 
C-H 
(stretching) 
2850-3000 cm
-1
 2973.40 cm
-1
 2936.75 cm
-1
 2937.71 cm
-1
 2936.75 cm
-1
 2938.68 cm
-1
 2943.50 cm
-1
 2934.82 cm
-1
 
6 
O-H 
(stretching) 
3200-3500 cm
-1
 3411.26 cm
-1 3258.81 cm-1 3397.26 cm-1 3272.38 cm-1 3273.34 cm-1 3261.77 cm-1 3271.41 cm-1 
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Figure No.5:FT-IR spectra of Nimodipine 
 
Figure No.6:FT-IR Spectra of Nimodipine withmannitol 
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Figure No.7:FT-IR Spectra of Nimodipine withmagnesium stearate 
 
 
Figure No.8:FT-IR Spectra of Nimodipine with microcrystalline cellulose 
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Figure No.9:FT-IR Spectra of Nimodipine with crospovidone 
 
 
Figure No.10:FT-IR Spectra of nimodipine with cross carmellose sodium 
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Figure No. 11:FT-IR Spectra of Nimodipine with sodium starch glycolate 
 
 FT-IR spectra of pure Nimodipine and the physical mixtures of drug and 
excipients were given in Table No. 12 and Figure No. 5, 6, 7, 8, 9, 10 and 11. Pure 
Nimodipine showed principal absorption peaks at 782.17 cm
-1
 (C-H aromatic 
bending), 1369.52cm
-1
 (NO2stretching), 1465.96 cm
-1
(C=C aromatic stretching), 1626.06 
cm
-1 
(N-H bending), 2973.40 cm
-1
 (C-H stretching) and 3411.26cm
-1
 (O-H stretching). 
The identical peaks ofC-H aromatic bending, NO2 stretching, C=C aromatic 
stretching, N-H bending, C-H stretching and O-H stretching, vibrations were also 
noticed in the spectra of physical mixtures which contains drug and excipients. FT-IR 
spectra revealed that there was no interaction between the drug and the excipients 
used for fast dissolving tablets preparation. 
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8.3. Precompression studies 
Table No. 13:Evaluation of tablet blend for formulations(F1-F9) 
Formulation 
Bulk 
Density 
(g/cc) 
Tapped 
Density(g/cc) 
Hausner’s 
ratio 
Compressibility 
index(%) 
Angle of 
repose 
F1 0.464 0.574 1.23 19.1 29.47 
F2 0.423 0.501 1.16 15.5 27.63 
F3 0.456 0.542 1.22 15.8 25.54 
F4 0.467 0.559 1.25 16.4 26.23 
F5 0.485 0.593 1.10 18.2 27.21 
F6 0.460 0.556 1.21 17.2 30.38 
F7 0.478 0.575 1.24 16.8 28.46 
F8 0.450 0.554 1.28 18.7 25.71 
F9 0.442 0.537 1.27 17.6 31.82 
 
 The angle of repose less than 32, which reveals good flow property it shown in for 
formulations F1 – F9.The loose bulk density and tapped bulk density for all 
formulation (F1 – F9) varied from 0.442 gm/cm3 to 0.467 gm/cm3 and 0.501 gm/cm3 
to 0.574 gm/cm
3respectively.The results of carr’s consolidate index or % 
compressibility index for the entire formulation (F1 – F9) blend range from 15 to 19 
shows fair flow properties. 
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8.4. Post compression studies 
Table No. 14:Evaluation of sublingual tablets for formulations (F1 – F9) 
Formulation 
Hardness 
(kg/cm2) 
Friability 
(%) 
Weight (mg) 
Thickness 
(mm) 
Drug 
conte
nt (%) 
F1 3.0±0.17 0.25 201±0.59 3.9±0.05 97.2 
F2 2.8±0.20 0.23 198±0.63 4±0.02 97.72 
F3 3.1±0.18 0.26 201±0.45 3.7±0.07 98.4 
F4 2.9±0.15 0.24 202±0.88 3.8±0.10 97 
F5 3.2±0.16 0.28 204±0.56 3.9±0.03 98.44 
F6 2.8±0.22 0.32 198±0.74 3.9±0.06 100.8 
F7 3.2±0.24 0.27 201±0.67 3.8±0.15 97.2 
F8 2.9±0.22 0.29 201±0.77 3.9±0.03 98.4 
F9 2.8±0.16 0.24 203±0.86 4±0.01 95.32 
 
The hardness values ranged from 2.8±0.16kg/cm
2
to 3.2±0.24 kg/cm
2   
for formulation 
(F1-F9) and were almost same. 
The friability values were found to be within the limit (0.5 - 1%). The above 
evaluation parameter showed no significant difference between F1, F2, F3, F4, F5, 
F6, F7, F8, F9 formulations. 
The entire tablet passes weight variation test as the average % weight variation was 
within the Pharmacopeia limit of 7.5%. It was found to be 198±0.63 mg to 204±0.56 
mg. The weight of all the tablets was found to be uniform with less deviation. 
The maximum concentration among all the formulations was found to be 100.8% and 
minimum % drug content from all formulation was found to be 95.32%. The results of 
drug content of all batches are shown in.  
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8.5. Evaluation of tablets 
Table No. 15:Evaluation of Sublingual tablets for formulations (F1 – F9) 
Formulation 
Disintegration 
time (sec) 
Wetting time 
(sec) 
Water 
absorption ratio 
(%) 
In vitro 
dispersion 
time (sec) 
F1 8 20 19.42 8 
F2 6 15 22.47 5 
F3 5 12 19.78 5 
F4 10 16 16.13 15 
F5 9 14 17.27 11 
F6 8 19 12.17 9 
F7 18 27 15.32 14 
F8 10 20 12.047 12 
F9 9 20 13.92 8 
 
Disintegration test carried out in modified dissolution apparatus, it shows the 
formulations with1.5%, 3%, 6% SSG showed high value for disintegrating time as 18, 
10, 8 secs. The results showed that the disintegration time of F1, F2, F3 with 1.5%, 
3%, 6% CP formulations to be as 8, 6, 5 secs respectively and is almost better than 
F4, F5, F6, F7, F8, F9 formulationsandcomparative profile. 
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Figure No. 12:Bar graph comparison between disintegration times for 
formulations (F1- F9) 
 
Wetting time is closely related to the inner structure of tablet. The experiment mimics 
the action of saliva in contact with the tablet to illustrate the water uptake and 
subsequent wetting of tablet. This shows the wetting process was very rapid in almost 
all formulations. This may be due to the ability of swelling followed by breaking and 
also capacity of water absorption and causes swelling. It was found to be in the range 
of 14 secs to 27secs.It shows crosspovidone formulations F1, F2, F3 (1.5 – 6%) have 
better wetting time comparing with that of cross carmellose sodium starch glycolate, 
and comparative profile result was shown in table no:15. 
Water absorption ratio which is important criteria for understanding the capacity of 
disintegrants to swell in the presence of little amount of water, was calculated. It was 
found to be in the range of 12.17 to 22.47% . This shows that all the formulations 
have good water absorption capacityresult was shown in table no:15. 
The in vitro dispersion time is measured by time taken to uniform dispersion, the 
rapid dispersion. It was found to be in the range of 5secs to 15secs (Graph). The result 
showed that the in vitro dispersion time of F1, F2, and F3 formulations is almost 
equal and better than F4, F5, F6, F7, F8, F9 formulations and comparative 
profileresult was shown in Table No:15. 
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Figure No. 13:Bar graph comparison between In-vitro dispersion times for 
formulations (F1- F9) 
8.5.1. In vitro dissolution studies 
Table No. 16:Cumulative % drug release for formulations (F1 – F9) 
Cumulative % drug release 
Time F1 F2 F3 F4 F5 F6 F7 F8 F9 
2 Min 55.15 58.9 65.5 48.07 51.5 62.7 45.93 50.54 57.9 
4 Min 68.6 72.1 74.9 57.29 61.5 71.1 55.97 61.7 61.07 
6 Min 71.12 80 82.64 72.93 76.55 81.16 71.44 73.2 77.2 
8 Min 81.9 87.08 89.06 79.68 84.61 86.5 76.05 81.8 84.12 
10 Min 91.17 94.82 96.96 88.4 93.3 94.1 85.2 87.07 89.2 
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Figure No. 14:Comparison between cumulative % drug releases for formulations 
(F1- F9) 
 
 
Figure No. 15:Comparison between cumulative % drug releases for formulations 
(F1- F3) 
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Figure No. 16:Comparison between cumulative % drug releases for formulations 
(F4 - F6) 
 
 
Figure No. 17:Comparison between cumulative % drug release for formulations 
(F7- F9) 
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Dissolution is carried out in USP-2 type apparatus at 50rpm in the volume of 500ml 
dissolution media (phosphate buffer pH 6.8) for 10 minutes. At the end of 10 minutes 
almost total amount of the drug is released (i.e. 96.96%), from the formulation 
prepared by the direct compression method with 6% crosspovidoneresult was shown 
in table no:16.  
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8.6. Drug release kinetics: 
Correlation coefficient (r) & rate constant (k) Values of Nimodipine sublingual tablets containing Crospovidone, cross carmellose sodium, 
sodium starch glycolate.  
Table No.17:Drug release kinetics 
 
 Kinetic 
model 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
Zero 
order 
r 0.9436 0.9391 0.9179 0.9364 0.9318 0.9151 0.9424 0.8383 0.8979 
k 17.15 18.25 18.72 14.32 15.37 17.77 13.99 15.42 15.42 
Higuchi 
r 0.9945 0.9913 0.9646 0.9943 0.9737 0.9833 0.9953 0.9927 0.9797 
k 35.17 37.09 39.09 29.63 31.80 37.17 28.82 31.76 32.71 
First 
order 
r 0.9963 0.9939 0.9991 0.9981 0.9994 0.9903 0.9989 0.9991 0.9822 
k 0.2697 0.3192 0.3456 0.2127 0.2466 0.3104 0.2057 0.241 0.24 
Peppas 
r 0.9796 0.9995 0.9985 0.9892 0.9914 0.9125 0.9914 0.9971 0.9615 
k 0.294 0.2894 0.2387 0.3878 0.3758 0.2511 0.3894 0.3489 0.2882 
Hixson-
crowell 
r 0.9659 0.9704 0.9626 0.9816 0.9855 0.859 0.9761 0.9741 0.9602 
k 0.3717 0.4022 0.4284 0.2865 0.3162 0.3932 0.2776 0.3177 0.3177 
DE10 44.73 47.48 51.48 38.36 41.13 49.13 36.96 40.47 44.38 
DE30 58.96 63.64 66.89 54.53 57.96 64.55 52.84 56.59 59.72 
T 50 1.81 1.70 1.53 2.42 1.94 1.59 2.81 1.98 1.73 
 T 90 9.75 8.75 8.24 0 9.28 8.92 0 0 0 
Department Of Pharmaceutics                                                     Results and discussion 
 
Annai Veilankanni’s Pharmacy College,Chennai 71 
 
 
 
Figure No. 18:First order plots of Nimodipine sublingual tabletscontaining 
crospovidone 
 
 
 
Figure No. 19: First order plots of Nimodipine sublingual tablets containing  
Croscarmellosesodium 
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Figure No.20: First order plots of Nimodipine sublingual tablets containing 
sodium starch glycolate 
 The drug release profiles of Nimodipine sublingual tablets were fitted to 
various kinetic models such as Zero order, First order, Higuchi, Peppasand Hixson-
Crowell. The dissolution parameters such as dissolution efficiency (DE) at 10 and 30 
minutes were increased proportionately. Half-life of drug i.e., T50 was found to be 
1.81, 1.70, 1.53, 2.42, 1.94, 1.59, 2.81, 1.98 and 1.73 min for F1, F2, F3, F4, F5, F6, 
F7, F8 and F9 formulations respectively. Shelf-life of the drug i.e., T90 was found to 
be 9.75, 8.75, 8.24, 9.28 and 8.92 minutes for F1, F2, F3, F5and F6 formulations 
respectively. The drug release data of nimodipine fast dissolving tablets have treated 
with different kinetic models are shown in Table No. 17.The drug release patterns of 
nimodipine fast dissolving tablets had followed the first order kinetic model. This 
release patterns are evident with the correlation coefficient ‘r’ values which are nearer 
to 1. The first order plots for all nimodipine fast dissolving tablets were shown in 
Figure No.18, 19 and 20. 
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8.7. Stability Study 
 
Table No. 18:Comparison of Various Parameters for Stability Study 
 
Evaluation 
Parameter 
Initial 1 month 2 month 3 month 
 
Hardness( kg/cm
2
) 
3.1 ± 0.18
 
3.2 ± 0.36 3.3 ± 0.05 3.3 ± 0.90 
 
% Friability 
0.26 0.25 0.24 0.24 
 
Disintegration 
Time (sec) 
5 7 sec 8 sec 9 sec 
Drug Content 98.4 99.6 99.2 99.80 
 
 The optimized formulation F3 is kept for stability studies. Accelerated 
stability studies were carried out at 40
0
C/75%RH for 3 months. The tablets were then 
evaluated for hardness, friability, disintegration and drug content at 1
st
 month, 2
nd
 
month and 3
rd
 month. The results indicated that there was no significant change in 
evaluation of the tablets. The results were tabulated in Table No: 18. 
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Table No. 19:Comparison of Drug Release Profile of Batch F3 
Time (min) Initial 1 month 2 month 3 month 
2 65.5 64.90 63.50 62.42 
4 74.9 73.71 72.25 71.64 
6 82.64 81.09 80.04 79.64 
9 89.06 88.90 87.25 86.09 
10 96.96 95.99 94.84 94.01 
 
 
 The optimized formulation F3 is evaluated for in-vitro drug release studies 
after keeping the tablets at accelerated stability conditions (40
0
C/75%RH) for 3 
months. It is evaluated initially, 1
st
 month, 2
nd
 month and 3
rd
 month. In-vitro drug 
release studies were performed in phosphate buffer pH 6.8 by using USP dissolution 
test apparatus-Type II, Rotating Paddle method. The results indicated that there was 
no significant change in in-vitro drug release studies. The data for in-vitro release 
profilewas shown in Table No: 19. 
 
 
 
Summary & Conclusion
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9. SUMMARY AND CONCLUSION 
9.1. Summary 
  The aim of the present study was to develop and optimize oral sublingual 
tablets of model drug (NMD) to give quick onset of action by rapidly disintegrating in 
a few seconds without the need of water with better patient compliance. In such cases, 
bioavailability of drug is significantly greater and adverse event is reduced than those 
observed from conventional tablet dosage form 
The work done is summarized as follows: 
By performing compatibility studies by IR spectrophotometry, no interaction was 
confirmed. Oral disintegrating tablets were formulated by direct compression  method 
and suitable analytical method based on UV-Visible spectrophotometer was developed 
for the model drug 
 Standard calibration curve prepared to determine the drug content in the prepared 
tablets and UV analysis was performed to determine the drug during in vitro release 
studies. 
 Prior to compression, the blend of drug and excipients were evaluated for flow 
properties such as Angle of repose, loose bulk density, Tapped density, % 
Compressibility, and Hausner’s ratio. All the formulations showed good flow 
properties. 
 Sublingual tablets were prepared by direct compression technique using 
CADMACH 16 station tablet punching machine, equipped with flat round punch of 
8.7 mm diameter. 
     Post compression evaluation of prepared sublingual tablets were carried out 
with the help of different pharmacopoeial and non pharmacopoeial (industry specified) 
tests. The shape and colour of all the formulations were found to be circular and white 
in colour. The thickness was found to be uniform in specific formulations. The 
hardness and friability are also within the permitted limits. 
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9.2. Conclusion 
 Sublingual tablets of nimodipine can be successfully prepared by direct 
compression method using selected superdisintegrants with Crosspovidone 1.5%, 3%, 
6%, Crosscarmellose 1.5%, 3%, 6% and Sodium starch glycolate 1.5%, 3%, 6%, for 
the better patient compliance and effective therapy the relative efficiency of these 
superdisintegrant to improve the disintegration and dissolution rate of tablets were 
found in order 
The disintegration of F1, F2, F3 with 1.5%, 3%, 6% Crosspovidone formulations to 
be as 8, 6, 5secs respectively and is almost better than F4, F5, F6, F7, F8, F9 
formulations 
Formulation F3 In-vitro Dissolution studie 10 minutes almost total amount of the drug 
is released 6% crosspovidone (i.e. 96.96%).  
Crosspovidone shows good result as compare to other superdisintegrants. 
Crosspovidone   >  crosscarmellose sodium  >  sodium starch glycolate 
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